To assess that long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective than corresponding placebo in the reduction of:

		Cardiovascular mortality,
		Cardiovascular mortality or hospitalizations for heart failure or for any reason
		Sudden cardiac death
		Hospitalizations for any reason
		Hospitalizations for cardiovascular reasons
		Hospitalizations for congestive heart failure
		Myocardial infarction
		Stroke